Machine learning risk stratification strategy for multiple myeloma: Insights from the EMN-HARMONY Alliance platform.
Saved in:
| Title: | Machine learning risk stratification strategy for multiple myeloma: Insights from the EMN-HARMONY Alliance platform. |
|---|---|
| Authors: | Mosquera Orgueira A; Department of Hematology, IDIS University Hospital of Santiago de Compostela Santiago de Compostela Spain., Gonzalez Perez MS; Department of Hematology, IDIS University Hospital of Santiago de Compostela Santiago de Compostela Spain., D'Agostino M; Division of Hematology, AOU Città della Salute e della Scienza di Torino University of Torino Torino Italy.; Department of Molecular Biotechnology and Health Sciences University of Torino Torino Italy., Cairns DA; Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research University of Leeds Leeds United Kingdom., Larocca A; Department of Molecular Biotechnology and Health Sciences, Division of Hematology University of Torino Torino Italy., Palacios JJL; Hospital Universitario 12 de Octubre CIBER-ONC CB16/12/00369, CNIO Madrid Spain., Wester R; Department of Hematology Erasmus MC Cancer Institute Rotterdam The Netherlands., Bertsch U; National Center for Tumor Diseases Heidelberg Heidelberg Germany.; Department of Medicine V, Heidelberg Myeloma Center University Hospital Heidelberg Heidelberg Germany., Waage A; Institute of Clinical and Molecular Medicine Norwegian University of Science and Technology and St. Olavs Hospital Trondheim Norway., Zamagni E; Department of Medical and Surgical Sciences, 'Seràgnoli' Institute of Hematology University of Bologna Bologna Italy.; IRCCS Azienda Ospedaliero-Universitaria di Bologna Bologna Italy., Pérez Míguez C; Department of Hematology, IDIS University Hospital of Santiago de Compostela Santiago de Compostela Spain., Rojas Martínez JA; Department of Hematology, IDIS University Hospital of Santiago de Compostela Santiago de Compostela Spain., Mai EK; Department of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg GMMG Study Group Heidelberg Germany., Crucitti D; Department of Hematology, IDIS University Hospital of Santiago de Compostela Santiago de Compostela Spain., Salwender H; Asklepios Tumorzentrum Hamburg Asklepios Hospital Hamburg Altona and St. Georg Hamburg Germany., Dall'Olio D; Department of Medical and Surgical Sciences (DIMEC) University of Bologna Bologna Italy., Castellani G; Department of Medical and Surgical Sciences (DIMEC) University of Bologna Bologna Italy., Piñeiro Fiel M; Department of Hematology, IDIS University Hospital of Santiago de Compostela Santiago de Compostela Spain., Bringhen S; AOU Città della Salute e della Scienza di Torino Torino Italy., Zweegman S; Department of Hematology, Amsterdam UMC, Cancer Center Amsterdam Vrije Universiteit Amsterdam Amsterdam The Netherlands., Cavo M; IRCCS Azienda Ospedaliero-Universitaria di Bologna Institute of Hematology 'L. e A. Seràgnoli' Bologna Italy.; Department of Medical and Surgical Sciences University of Bologna Bologna Italy., Iqbal S; Medical Information Scientific Engagement Johnson & Johnson Innovative Medicines New York New York United States., Hernandez Rivas JM; Department of Medicine, Cancer Research Center (IBMCC, USAL-CSIC), Institute of Biomedical Research of Salamanca (IBSAL) University of Salamanca Salamanca Spain., Bruno B; Division of Hematology, AOU Città della Salute e della Scienza di Torino University of Torino Torino Italy.; Department of Molecular Biotechnology and Health Sciences University of Torino Torino Italy., Cook G; Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research University of Leeds Leeds United Kingdom., Kaiser MF; Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research University of Leeds Leeds United Kingdom.; The Institute of Cancer Research and the Royal Marsden Hospital London United Kingdom., Goldschmidt H; National Center for Tumor Diseases Heidelberg Heidelberg Germany.; Department of Medicine V, Heidelberg Myeloma Center University Hospital Heidelberg Heidelberg Germany., Van De Donk NWCJ; Department of Hematology, Amsterdam UMC, Cancer Center Amsterdam Vrije Universiteit Amsterdam Amsterdam The Netherlands., Jackson G; Department of Haematology Newcastle University Newcastle Upon Tyne United Kingdom., San-Miguel JF; Clínica Universidad de Navarra CIMA, IDISNA, CIBERONC (CB16/12/00369) Pamplona Spain., Boccadoro M; European Myeloma Network (EMN) Italy., Mateos MV; Department of Medicine, Cancer Research Center (IBMCC, USAL-CSIC), Institute of Biomedical Research of Salamanca (IBSAL) University of Salamanca Salamanca Spain., Sonneveld P; Department of Hematology Erasmus MC Cancer Institute Rotterdam The Netherlands. |
| Source: | HemaSphere [Hemasphere] 2025 Oct 09; Vol. 9 (10), pp. e70228. Date of Electronic Publication: 2025 Oct 09 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 101740619 Publication Model: eCollection Cited Medium: Internet ISSN: 2572-9241 (Electronic) Linking ISSN: 25729241 NLM ISO Abbreviation: Hemasphere Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
